RNA sequencing/Gene expression studies of CSK inhibitor (CSKi) in diffuse large B-cell lymphoma (DLBCL) [JC2]
We determined that CSKi treatment affects oncogenic signaling in DLBCL. We sought to measure gene expression change in DLBCL cells by RNA-sequencing following CSKi treatment. Overall design: TMD8 and DOHH2 cells were treated in duplicates with DMSO or CSKi (500nm) for 1h, 3h, 6h and 24h.